Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out
in the Schedule hereto:
Schedule
Product: Pneumo 23
Active Ingredients: Pneumococcal Polysaccharide type 1 25µg
Pneumococcal Polysaccharide type 10A 25µg
Pneumococcal Polysaccharide type 11A 25µg
Pneumococcal Polysaccharide type 12F 25µg
Pneumococcal Polysaccharide type 14 25µg
Pneumococcal Polysaccharide type 15B 25µg
Pneumococcal Polysaccharide type 17F 25µg
Pneumococcal Polysaccharide type 18C 25µg
Pneumococcal Polysaccharide type 19A 25µg
Pneumococcal Polysaccharide type 19F 25µg
Pneumococcal Polysaccharide type 2 25µg
Pneumococcal Polysaccharide type 20 25µg
Pneumococcal Polysaccharide type 22F 25µg
Pneumococcal Polysaccharide type 23F 25µg
Pneumococcal Polysaccharide type 3 25µg
Pneumococcal Polysaccharide type 33F 25µg
Pneumococcal Polysaccharide type 4 25µg
Pneumococcal Polysaccharide type 5 25µg
Pneumococcal Polysaccharide type 6B 25µg
Pneumococcal Polysaccharide type 7F 25µg
Pneumococcal Polysaccharide type 8 25µg
Pneumococcal Polysaccharide type 9N 25µg
Pneumococcal Polysaccharide type 9V 25µg
Dosage Form: Suspension for injection
New Zealand Sponsor: sanofi-aventis new zealand limited
Manufacturer: Sanofi Pasteur SA, Marcy L’Etoile, France
Dated this 10th day of November 2011.
DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).